Provided by Tiger Trade Technology Pte. Ltd.

Unicycive Therapeutics, Inc.

4.09
-0.0900-2.15%
Volume:95.13K
Turnover:389.90K
Market Cap:113.93M
PE:-2.62
High:4.20
Open:4.20
Low:4.07
Close:4.18
52wk High:8.74
52wk Low:3.93
Shares:27.86M
Float Shares:26.68M
Volume Ratio:2.50
T/O Rate:0.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5585
EPS(LYR):-1.6715
ROE:-101.07%
ROA:-40.59%
PB:2.14
PE(LYR):-2.45

Loading ...

Unicycive Therapeutics Posts Corporate Presentation on Kidney Disease Drug Pipeline, Led by OLC for Dialysis Hyperphosphatemia

Reuters
·
Aug 17

Clene Q2 Net Loss Widens on Higher Other Expenses

Reuters
·
Aug 14

Eledon Pharmaceuticals Q2 Net Loss Widens on Warrant Liability Changes

Reuters
·
Aug 14

Unicycive Therapeutics Price Target Cut to $20.00/Share from $22.00 by B. Riley Securities

Dow Jones
·
Aug 13

B. Riley Securities Reaffirms Their Buy Rating on Unicycive Therapeutics (UNCY)

TIPRANKS
·
Aug 13

B. Riley Adjusts Price Target on Unicycive Therapeutics to $20 From $22, Maintains Buy Rating

MT Newswires Live
·
Aug 13

Unicycive Therapeutics Inc : Guggenheim Cuts Target Price to $25 from $37

THOMSON REUTERS
·
Aug 13

Inovio Q2 Net Loss Narrows on Warrant Gain, Lower Costs

Reuters
·
Aug 13

Unicycive Rises on Narrower Quarterly Loss

Reuters
·
Aug 13

Unicycive Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 12

Unicycive Therapeutics Q2 Net Loss Narrows on Warrant Liability Change

Reuters
·
Aug 12

Unicycive Therapeutics Q2 EPS USD -0.06

THOMSON REUTERS
·
Aug 12

Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update

THOMSON REUTERS
·
Aug 12

Unicycive Therapeutics - Q2 Net Loss was $1.70 Mln or $0.06 Per Share

THOMSON REUTERS
·
Aug 12

Unicycive Therapeutics Q2 EPS $(0.06) Beats $(0.34) Estimate

Benzinga Earnings
·
Aug 12

Unicycive Net Loss Widens 147% to USD 14.55 Million in FY26 First Half

Reuters
·
Aug 12

Unicycive Therapeutics Inc Expected to Post a Loss of 34 Cents a Share - Earnings Preview

Reuters
·
Aug 10

Unicycive Therapeutics Publishes Corporate Presentation on Kidney Disease Drug Pipeline

Reuters
·
Aug 01

Unicycive Therapeutics Posts Corporate Presentation on Kidney Disease Pipeline, Lead Hyperphosphatemia Drug OLC

Reuters
·
Jul 07

Unicycive Therapeutics Gets Complete Response Letter from FDA on Resubmitted Oxylanthanum Carbonate NDA

Reuters
·
Jul 06